MYDA Advisors LLC Invests $136,000 in EQRx, Inc. (NASDAQ:EQRX)

MYDA Advisors LLC acquired a new position in shares of EQRx, Inc. (NASDAQ:EQRXGet Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $136,000.

Other institutional investors also recently bought and sold shares of the company. Advisor Group Holdings Inc. purchased a new stake in shares of EQRx during the fourth quarter worth $67,000. Brown Advisory Inc. acquired a new position in shares of EQRx during the fourth quarter worth $84,000. Texas Yale Capital Corp. acquired a new position in shares of EQRx during the fourth quarter worth $136,000. Cannon Global Investment Management LLC acquired a new position in shares of EQRx during the fourth quarter worth $171,000. Finally, Northern Trust Corp acquired a new position in shares of EQRx during the fourth quarter worth $329,000. 69.24% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts recently commented on the stock. Cowen assumed coverage on shares of EQRx in a research note on Friday, April 22nd. They set an “outperform” rating for the company. Cowen assumed coverage on shares of EQRx in a research note on Friday, April 22nd. They set an “outperform” rating for the company. Finally, Jefferies Financial Group initiated coverage on shares of EQRx in a research note on Friday, March 18th. They set a “buy” rating and a $5.60 target price for the company.

NASDAQ EQRX traded up $0.04 during trading hours on Wednesday, hitting $4.80. The company had a trading volume of 13,938 shares, compared to its average volume of 1,230,781. EQRx, Inc. has a 1-year low of $2.63 and a 1-year high of $11.10. The firm has a 50 day moving average of $4.23.

EQRx (NASDAQ:EQRXGet Rating) last released its quarterly earnings data on Friday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.34. As a group, sell-side analysts anticipate that EQRx, Inc. will post -1.02 earnings per share for the current year.

EQRx Profile (Get Rating)

EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.

Read More

Want to see what other hedge funds are holding EQRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EQRx, Inc. (NASDAQ:EQRXGet Rating).

Institutional Ownership by Quarter for EQRx (NASDAQ:EQRX)

Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.